These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 2479848)

  • 21. Effects of idiotypic human anti-mouse antibody against in vitro binding and antitumor activity of a monoclonal antibody-drug conjugate.
    Otsuji E; Tsuruta H; Toma A; Kobayashi S; Okamoto K; Yata Y; Yamagishi H
    Hepatogastroenterology; 2003; 50(50):380-4. PubMed ID: 12749227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Additive effects of bleomycin and neocarzinostatin on degradation of DNA, inhibition of DNA polymerase beta, and cell growth.
    Müller WE; Maidhof A; Arendes J; Geurtsen W; Zahn RK; Schmidseder R
    Cancer Res; 1979 Sep; 39(9):3768-73. PubMed ID: 89904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Absorption, distribution and excretion of neocarzinostatin (NCS) in mice after oral administration.
    Toriyama K; Fujita H; Ishida N
    J Antibiot (Tokyo); 1975 Jan; 28(1):64-72. PubMed ID: 123896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of accumulation of the antitumor protein antibiotic neocarzinostatin in bladder tissue: intravenous administration, urinary excretion, and absorption into bladder tissue.
    Maeda H; Sakamoto S; Ogata J
    Antimicrob Agents Chemother; 1977 Jun; 11(6):941-5. PubMed ID: 141906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binding, internalization and the cytotoxicity of monoclonal antibody A7-neocarzinostatin conjugates (A7-NCS) in target cells.
    Kitamura K; Takahashi T; Noguchi A; Takashina K; Tsurumi H; Yamaguchi T
    Tohoku J Exp Med; 1990 Jul; 161(3):199-207. PubMed ID: 2147302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kinetic analysis of the in vitro cell-killing action of neocarzinostatin.
    Ozawa S; Inaba M
    Cancer Chemother Pharmacol; 1989; 23(5):279-82. PubMed ID: 2523252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The biological effect of a nonprotein component removed from neocarzinostatin (NCS).
    Ohtsuki K; Ishida N
    J Antibiot (Tokyo); 1980 Jul; 33(7):744-50. PubMed ID: 6447677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The effects of neocarzinostatin on superoxide production by monocyte-derived macrophages].
    Ouchi E; Honnda I; Wakui A; Kikuchi K; Ishida N
    Gan No Rinsho; 1986 Apr; 32(4):387-91. PubMed ID: 3012141
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanism of free and conjugated neocarzinostatin activity: studies on chromophore and protein uptake using a transferrin-neocarzinostatin conjugate.
    Schönlau F; Maibücher A; Köhnlein W; Garnett MC
    Z Naturforsch C J Biosci; 1997; 52(3-4):245-54. PubMed ID: 9167276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Part I. Theory and computer simulation for cerebrospinal infusion].
    Maeda H; Matsukado Y; Iwai Z; Uemura S; Kuratsu J; Takeshita J; Sano Y
    Gan To Kagaku Ryoho; 1982 Jul; 9(6):1040-5. PubMed ID: 6223592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Missile therapy of colorectal and pancreatic cancers--clinical trial of monoclonal antibody, A7-NCS, in 73 patients with colorectal and pancreatic cancers].
    Takahashi T; Yamaguchi T; Kitamura K; Noguchi A; Honda M; Otsuji E
    Gan To Kagaku Ryoho; 1990 Jun; 17(6):1111-9. PubMed ID: 2140933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Applicability of monoclonal antibody Fab fragments as a carrier of neocarzinostatin in targeting chemotherapy.
    Otsuji E; Yamaguchi T; Tsuruta H; Yata Y; Nishi H; Okamoto K; Taniguchi K; Kato M; Kotani T; Kitamura K; Takahashi T
    J Surg Oncol; 1996 Feb; 61(2):149-54. PubMed ID: 8606548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative study on the pharmacokinetics and biodistribution of boronated porphyrin (BOPP) and sulfhydryl boron hydride (BSH) in the RG2 rat glioma model.
    Ceberg CP; Brun A; Kahl SB; Koo MS; Persson BR; Salford LG
    J Neurosurg; 1995 Jul; 83(1):86-92. PubMed ID: 7782856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of recombinant human tumor necrosis factor on rodent gliomas and normal brain.
    Kiwit JC; Schmitz KH; Daum L; Reifenberger G; Roosen N
    J Neurosurg; 1991 Oct; 75(4):597-603. PubMed ID: 1653310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting immunotherapy using the avidin-biotin system for a human colon adenocarcinoma in vitro.
    Nakaki M; Takikawa H; Yamanaka M
    J Int Med Res; 1997; 25(1):14-23. PubMed ID: 9027669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioimmunoassay of neocarzinostatin, an antitumor protein.
    Samy TS; Raso V
    Cancer Res; 1976 Dec; 36(12):4378-81. PubMed ID: 63321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unusual survival kinetics of neocarzinostatin-treated HeLa cells: its relation to the drug-inactivation.
    Kuroda Y; Sasaki T; Hoshino F
    J Radiat Res; 1991 Jun; 32(2):191-201. PubMed ID: 1834831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Screening for antagonistic agents to the lethal toxicity of neocarzinostatin. II. Effects of various drugs in inhibiting the toxicity of neocarzinostatin in vivo].
    Ouchi M; Toriyama K; Matsumoto T; Baba T
    Jpn J Antibiot; 1988 Jan; 41(1):105-15. PubMed ID: 2966869
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glutathione dependence of neocarzinostatin cytotoxicity and mutagenicity in Chinese hamster V-79 cells.
    DeGraff WG; Mitchell JB
    Cancer Res; 1985 Oct; 45(10):4760-2. PubMed ID: 3161610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro mode of action, pharmacokinetics, and organ specificity of poly (maleic acid-styrene)-conjugated neocarzinostatin, SMANCS.
    Takeshita J; Maeda H; Kanamaru R
    Gan; 1982 Apr; 73(2):278-84. PubMed ID: 6214446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.